Four disruptive strategies for removing drug discovery bottlenecks.

Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the USA, with little coordination or consideration of the outputs and creating a translational gap. Although there have been collaborative public-private partnerships in Europe to share pharmaceutical data, the USA has seemingly lagged behind and this may hold it back. Sharing precompetitive data and models may accelerate discovery across the board, while finding the best collaborators, mining social media and mobile approaches to open drug discovery should be evaluated in our efforts to remove drug discovery bottlenecks. We describe four strategies to rectify the current unsustainable situation.

• Publication year

  2013

• Venue

  Drug Discovery Today

• Publication date

  2013-03-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1016/j.drudis.2012.10.007PMID 23098820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Open PHACTS: semantic interoperability for drug discovery.

  2012cited by this paper
• The Value of Failures in Pharmaceutical R&D

  2012cited by this paper
• Open Drug Discovery Teams: A Chemistry Mobile App for Collaboration

  2012cited by this paper
• Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models

  2012cited by this paper
• Redefining Cheminformatics with Intuitive Collaborative Mobile Apps

  2012cited by this paper
• Identification of drug modulators targeting gene-dosage disease CMT1A.

  2012cited by this paper
• Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation.

  2012cited by this paper
• BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results

  2011cited by this paper
• Reengineering Translational Science: The Time Is Right

  2011cited by this paper
• Withdrawal of clinical trials policy by Canadian research institute is a “lost opportunity for increased transparency”

  2011cited by this paper
• Impact of high-throughput screening in biomedical research

  2011cited by this paper
• Alternative business models for drug discovery.

  2011cited by this paper
• A quality alert and call for improved curation of public chemistry databases.

  2011cited by this paper
• Current and Future Challenges for Collaborative Computational Technologies for the Life Sciences

  2011cited by this paper
• Collaboration versus outsourcing: the need to think outside the box.

  2011cited by this paper
• Minimum information about a bioactive entity (MIABE)

  2011cited by this paper
• Believe it or not: how much can we rely on published data on potential drug targets?

  2011cited by this paper
• The Precompetitive Space: Time to Move the Yardsticks

  2011cited by this paper
• Translating Clinical Findings into Knowledge in Drug Safety Evaluation - Drug Induced Liver Injury Prediction System (DILIps)

  2011cited by this paper
• Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines

  2011cited by this paper
• The Use of Twitter to Track Levels of Disease Activity and Public Concern in the U.S. during the Influenza A H1N1 Pandemic

  2011cited by this paper
• In silico repositioning of approved drugs for rare and neglected diseases.

  2011cited by this paper
• The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

  2011cited by this paper
• Predicting individual affect of health interventions to reduce HPV prevalence.

  2011cited by this paper
• Mobile apps for chemistry in the world of drug discovery.

  2011cited by this paper
• US academic drug discovery

  2011cited by this paper
• A collaborative database and computational models for tuberculosis drug discovery.

  2010cited by this paper
• A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• Towards interoperable and reproducible QSAR analyses: Exchange of datasets

  2010cited by this paper
• Predicting protein structures with a multiplayer online game

  2010cited by this paper
• Collaborative development of predictive toxicology applications

  2010cited by this paper
• Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties

  2010cited by this paper
• Editorial survey: swarm intelligence for data mining

  2010cited by this paper
• Pandemics in the Age of Twitter: Content Analysis of Tweets during the 2009 H1N1 Outbreak

  2010cited by this paper
• Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.

  2010cited by this paper
• Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.

  2010cited by this paper
• Informatics for neglected diseases collaborations.

  2010cited by this paper
• ChemSpider:: An Online Chemical Information Resource

  2010cited by this paper
• Collaboration: Social networking seeks critical mass

  2010cited by this paper
• Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.

  2009cited by this paper
• Clinical research for rare disease: opportunities, challenges, and solutions.

  2009cited by this paper
• Drug development for orphan diseases in the context of personalized medicine.

  2009cited by this paper
• A crowdsourcing evaluation of the NIH chemical probes.

  2009cited by this paper
• Internet-based tools for communication and collaboration in chemistry.

  2008cited by this paper
• The Toxicity Data Landscape for Environmental Chemicals

  2008cited by this paper
• The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients.

  2008cited by this paper
• Drugs for bad bugs: confronting the challenges of antibacterial discovery

  2007cited by this paper
• Clinical attrition due to biased preclinical assessments of potential efficacy.

  2007cited by this paper
• The ToxCast program for prioritizing toxicity testing of environmental chemicals.

  2007cited by this paper
• Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis

  2006cited by this paper
• Drug discovery alliances

  2005cited by this paper
• Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations.

  2005cited by this paper
• R & D collaboration on trial

  1994cited by this paper

• Generative AI, Emerging Technology, and Organizing: Towards a theory of progressive encapsulation

  2024cites this paper
• Making more of less: using divestitures to unlock pharmaceutical innovation.

  2024cites this paper
• Network Analysis of Molecular Dynamics Sectors in the p53 Protein

  2022cites this paper
• Moving drug discoveries beyond the valley of death: the role of innovation ecosystems

  2020cites this paper
• Partnerships for better neglected disease drug discovery and development: how have we fared?

  2020cites this paper
• Biopharmaceutical Entrepreneurship, Open Innovation, and the Knowledge Economy

  2019cites this paper
• When more isn't merrier: pharmaceutical alliance networks and breakthrough innovation.

  2019cites this paper
• Data Mining and Computational Modeling of High-Throughput Screening Datasets.

  2018cites this paper
• When fragments link: a bibliometric perspective on the development of fragment-based drug discovery.

  2018cites this paper
• Outlook for the Future

  2017cites this paper
• Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

  2017cites this paper
• Changing R&D models in research-based pharmaceutical companies

  2016cites this paper
• Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

  2016cites this paper
• Enabling Anyone to Translate Clinically Relevant Ideas to Therapies

  2016cites this paper
• Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise

  2016cites this paper
• Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization.

  2016cites this paper
• Ionic liquids as a potential tool for drug delivery systems

  2016cites this paper
• High Throughput Screening with Biofabrication Platforms

  2015cites this paper
• A brief review of recent Charcot-Marie-Tooth research and priorities

  2015cites this paper
• Can medical products be developed on a non-profit basis? Exploring product development partnerships for neglected diseases

  2015cites this paper
• Institutions, Innovation and Public Health

  2015cites this paper
• An analysis of original research contributions toward FDA-approved drugs.

  2015cites this paper
• Attrition in Drug Discovery and Development

  2015cites this paper
• Accessing external innovation in drug discovery and development

  2015cites this paper
• Mobilizing patient data towards precision medicine

  2014cites this paper
• Curing TB with open science.

  2014cites this paper
• Use of Freely Available and Open Source Tools for In Silico Screening in Chemical Biology

  2014cites this paper
• Bigger data, collaborative tools and the future of predictive drug discovery

  2014cites this paper
• Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.

  2014cites this paper
• Cheminformatics: Mobile Workflows and Data Sources

  2014cites this paper
• Background Paper 8.1 Public Private Partnerships

  2013cites this paper
• priority Medicines for Europe and the World: 2013 update

  2013cites this paper
• Alzheimer's disease public‐private partnerships: A landscape of the global nonprofit community

  2013cites this paper
• Research News Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community

  2013cites this paper
• Improving data and knowledge management to better integrate health care and research

  2013cites this paper
• Cheminformatics workflows using mobile apps

  2013cites this paper
• Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.

  2013cites this paper
• Innovation in academic chemical screening: filling the gaps in chemical biology.

  2013cites this paper
• How to improve data and knowledge management to better integrate healthcare and research

  2013cites this paper